Natural History Study of Retinitis Pigmentosa Type 11

NCT ID: NCT04805658

Last Updated: 2025-03-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2028-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study of patients with retinitis pigmentosa type 11

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Natural history study with clinical examination every 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinitis Pigmentosa 11 Retinitis Pigmentosa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical examinations

Clinical examinations

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of retinitis pigmentosa caused by a disease-causing mutation involving the PRPF31 gene
* Or disease-causing mutation involving the PRPF31 gene without the clinical diagnosis of retinitis pigmentosa

Exclusion Criteria

* Under 18 years
* Other types of retinitis pigmentosa
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oslo University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Josephine Prener Holtan

Senior Consultant, MD PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Josephine P Holtan, MD, PHD

Role: PRINCIPAL_INVESTIGATOR

Department of Ophthalmology, Oslo University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Ophthalmology, Oslo University Hospital

Oslo, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

179417

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.